Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Individualized Care Perceptions of Patients Receiving Outpatient Chemotherapy: A Qualitative Study

NCT07536945 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-05-01
Last updated
2026-04-23

Condition(s) studied

Cancer PatientsCareChemotherapy

Study summary

The purpose of this observational study is to learn how people receiving chemotherapy in a clinic without staying overnight (outpatient) feel about the care they receive. The study focuses on individualized care, which means nursing care that is tailored specifically to each person's unique needs, values, and lifestyle.

Background:

Cancer treatment often involves chemotherapy (medicine used to kill cancer cells). While these treatments help fight the disease, they can also cause side effects like nausea or tiredness, which affect daily life. Nurses play a key role in helping people manage these effects. This research aims to understand how "individualized care" helps participants feel valued and supported during their treatment journey.

The study aims to answer these key questions:

How do participants describe their experiences with nursing care?

What are the specific needs and expectations of these individuals for care that feels personal to them?

How does personalized care affect their ability to manage symptoms and follow their treatment plan?

Scope and Setting:

This study will take place at the Yalova Training and Research Hospital within the Outpatient Chemotherapy Unit. The research will be conducted between May 1, 2026, and April 1, 2027.

Method and Participants:

The researchers plan to interview 10 to 20 participants who are over 18 years old and receiving treatment at the clinic. The final number of participants will be decided when the researchers find that no new information or themes are being discovered in the interviews (a stage called "data saturation").

Participants will:

Take part in a private, one-on-one interview with a researcher.

Answer open-ended questions about their thoughts and feelings regarding their nursing care.

Allow the interview to be voice-recorded to ensure all information is captured accurately.

Spend approximately 30 to 45 minutes sharing their personal experiences.

Privacy and Ethics:

Participant privacy is a top priority. All personal information and voice recordings will be kept strictly confidential. In the final report, fake names (aliases) will be used so that no one can be identified. Participants can choose to leave the study at any time. The study follows international ethical rules to protect the rights of every participant.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Continuing treatment at the Outpatient Chemotherapy Unit of the relevant hospital. * Voluntarily agreeing to participate in the study. * Being over 18 years of age. * Being proficient in Turkish. * Exclusion Criteria: * Not receiving ongoing treatment at the Outpatient Chemotherapy Unit of the relevant hospital. * Declining to participate in the study voluntarily. * Unwillingness to answer questions or lack of cooperation during the interview.

Primary outcome measure(s)

  • Number of participants expressing specific themes regarding perceptions of individualized nursing care. — Through study completion (approximately 12 months).
    This outcome measures the frequency and depth of perceptions of individualized nursing care as shared by participants during semi-structured interviews. Data will be analyzed using descriptive and thematic analysis. The results will be reported as the identified themes and the number of participants who expressed each specific theme or perception.

Trial sites (1)

FacilityCityRegionStatus
University Of Yalova Yalova Yalova
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07536945 on ClinicalTrials.gov ↗ ← All trials in Turkey